Jazz Pharmaceuticals Ireland Ltd
Jazz Pharmaceuticals Ireland Ltd is a pharmaceutical drug manufacturer / distributor from Athlone, Ireland with revenues of over $1.618 billion annually in 2017[1].
Overview
Jazz Pharmaceuticals is an Ireland based global biopharmaceutical company with the following lead products.
- Xyrem® (sodium oxybate) oral solution, the only product approved by the U.S. Food and Drug Administration, or FDA, and marketed in the U.S. for the treatment of both cataplexy and excessive daytime sleepiness, or EDS, in both adult and pediatric patients with narcolepsy;
- Sunosi® (solriamfetol), a product approved by the FDA and marketed in the U.S. to improve wakefulness in adult patients with EDS associated with narcolepsy or obstructive sleep apnea, or OSA, and also approved in Europe in January 2020 by the European Commission, or EC;
- Defitelio® (defibrotide sodium), a product approved in the U.S. for the treatment of adult and pediatric patients with hepatic veno-occlusive disease, or VOD, also known as sinusoidal obstruction syndrome, or SOS, with renal or pulmonary dysfunction following hematopoietic stem cell transplantation, or HSCT, and in Europe (where it is marketed as Defitelio® (defibrotide)) for the treatment of severe VOD in adults and children undergoing HSCT therapy;
- Erwinaze® (asparaginase Erwinia chrysanthemi), a treatment approved in the U.S. and in certain markets in Europe (where it is marketed as Erwinase®) for patients with acute lymphoblastic leukemia, or ALL, who have developed hypersensitivity to E. coli-derived asparaginase; and
- Vyxeos® (daunorubicin and cytarabine) liposome for injection, a product approved in the U.S. and in Europe (where it is marketed as Vyxeos® liposomal 44 mg/100 mg powder for concentrate for solution for infusion) for the treatment of adults with newly-diagnosed therapyrelated acute myeloid leukemia, or t-AML, or AML with myelodysplasia-related changes, or AML-MRC.
History
Major acquisitions
In January 2021, Jazz announced it would acquire GW Pharmaceuticals for $7.2 billion.
Board of directors
- Peter Gray, Chairman, Teckro, Inc. and Director
- Bruce C. Cozadd Chairman and Chief Executive Officer, Jazz Pharmaceuticals plc
- Abzena Kenneth W. O’Keefe, Managing Director, Beecken Petty O’Keefe & Company
- Mark D. Smith, M.D. Professor, University of California, San Francisco and Director, Teladoc Health, Inc. and Phreesia, Inc.
- Catherine A. Sohn, Pharm.D. Chairperson, BioEclipse Therapeutics, Inc. and Director, Axcella Health Inc., Landec Corporation and Rubius Therapeutics
- Jennifer E. Cook Director, BridgeBio Pharma, Inc. and Denali Therapeutics Inc.
- Patrick G. Enright Managing Director, Longitude Capital
- Heather Ann McSharry Director, International Airlines Group, S.A.
- Seamus Mulligan Director, Jazz Pharmaceuticals plc
- Anne O’Riordan Group Director of Digital, Jardine Matheson Limited
- Norbert G. Riedel, Ph.D. Chief Executive Officer, Aptinyx Inc.
- Rick E Winningham Chairman and Chief Executive Officer, Theravance Biopharma, Inc.
Products in development
JZP458
Cannabidiol
- Epilepsy with myoclonic-atonic seizures (EMAS)
Nabiximols
Lurbinectedin
- 1L treatment SCLC(small cell lung cancer), in combination with atezolizumab
- Basket trial: advanced urothelial cancer, large cell neuroendocrine tumor of the lung, HRD+ cancers
JZP351
- AML or HR-MDS >60 yrs (AML18)
- Newly diagnosed adults with standard - and HR-AML (AMLSG)
- Newly diagnosed <22 yrs with AML (COG)
- HR-MDS (EMSCO)
- Newly diagnosed older adults with HRAML
- Low Intensity Dosing for higher risk MDS
JZP351 + venetoclax
- De novo AML
- Relapsed refractory AML
JZP351 + other approved therapies
- R/R AML or HMA Failure MDS2
- First-line, fit AML (Phase 1b)
- Low Intensity Therapy for first-line, unfit AML (Phase 1b)
Suvecaltamide (JZP385)
- Essential tremor (Phase 2b)
JZP150
JZP324
- Oxybate extended-release formulation
CombiPlex
- Exploratory activities
Pre-clinical
Exosome candidates
- Exosome NRAS
- Solid tumors/Hematological malignancies
Pre-clinical
JZP341
- ALL/LBL
Pre-clinical
Pan-RAF Inhibitor Program
- RAF & RAS mutant tumors
External links
Reviews & Ratings
- Familiar with Familiar with Jazz Pharmaceuticals ? Write a review
- Reviews(external)
- Rating Criteria: 5 Stars – Outstanding, 1 Star – Unsatisfactory
1
Awards
- Nominate Jazz Pharmaceuticals Ireland Ltd for an outstanding quality / service award!
Resources
Frequently asked questions
Additional resources | |
|---|---|
Jazz Pharmaceuticals Ireland Ltd | |
| Videos |
] on YouTube |
| About WikiMD |  |
 | This Jazz Pharmaceuticals Ireland Ltd article is a stub. You can help Wikipedia by expanding it. |
WikiMD needs you!
This WikiMD article Jazz Pharmaceuticals Ireland Ltd is a stub.
If you are a subject matter expert or authority on Jazz Pharmaceuticals Ireland Ltd, you can help us.
About | Mission | Paid editors welcome. WikiMD needs you!
- ↑ "Jazz Pharmaceuticals PLC 2017 Annual Report (Form 10-K)". sec.gov. U.S. Securities and Exchange Commission. February 2018. Archived from the original on 2018-04-16. Retrieved 2018-07-19.
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
